指南与共识冠心病血脂与心血管预防

当代冠状动脉血运重建试验中指南导向药物治疗的依从性

Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials.
指南 / 共识 · J Am Coll Cardiol · 2018-01-01

该研究检索2005年至2017年8月的随机对照试验,比较药物洗脱支架PCI与CABG并报告血运重建后药物治疗的5项试验。结果显示GDMT1依从性从1年67%降至5年53%,GDMT2从40%降至38%,且PCI在各时间点均高于CABG。Meta回归提示GDMT1使用较低与PCI相比CABG的5年不良临床结局相关。

要点

  • 冠脉血运重建试验中GDMT依从性低且随时间下降,5年时GDMT1仅53%。
  • CABG后GDMT依从性显著低于PCI,可能影响试验终点比较。
  • GDMT1使用较低与PCI相比CABG的5年不良结局相关。

核心结论

  • 当代临床试验中GDMT依从性仍不理想,CABG后显著低于PCI,可能影响两组临床终点比较。

研究设计与样本

  • 检索Cochrane Central Register of Controlled Trials和MEDLINE(2005年至2017年8月)及试验注册库和参考文献。
  • 纳入比较药物洗脱支架PCI与CABG并报告血运重建后药物治疗的随机对照试验,共纳入5项试验。
  • GDMT1定义为任何抗血小板药+β受体阻滞剂+他汀;GDMT2定义为GDMT1+ACEI/ARB。

主要发现

  • GDMT1依从性从1年67%降至5年53%。
  • GDMT2依从性从1年40%降至5年38%。
  • PCI在各时间点GDMT1和GDMT2依从性均高于CABG。
  • Meta回归提示GDMT1使用较低与PCI相比CABG的5年不良临床结局相关。

临床怎么用

  • 在冠脉血运重建后应重视并提高GDMT依从性,尤其CABG后。
  • 解读PCI与CABG对比试验时需考虑药物治疗依从性差异对结局的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the well-established benefits of secondary cardiovascular prevention, the importance of concurrent medical therapy in clinical trials of coronary revascularization is often overlooked. OBJECTIVES: The goal of this study was to assess compliance with guideline-directed medical therapy (GDMT) in clinical trials and its potential impact on the comparison between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). METHODS: The Cochrane Central Register of Controlled Trials and MEDLINE were searched from 2005 to August 2017. Clinical trial registries and reference lists of relevant studies were also searched. Randomized controlled trials comparing PCI with drug-eluting stents versus CABG and reporting medical therapy after revascularization were included. The study outcome was compliance with GDMT, defined as the following: 1) any antiplatelet agent plus beta-blocker plus statin (GDMT1); and 2) any antiplatelet agent plus beta-blocker plus statin plus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (GDMT2). Data collection and analysis were performed according to the methodological recommendations of The Cochrane Collaboration. RESULTS: From a total of 439 references, 5 trials were included based on our inclusion and exclusion criteria. Overall, compliance with GDMT1 was low and decreased over time from 67% at 1 year to 53% at 5 years. Compliance with GDMT2 was even lower and decreased from 40% at 1 year to 38% at 5 years. Compliance with both GDMT1 and GDMT2 was higher in PCI than in CABG at all time points. Meta-regression suggested an association between lower use of GDMT1 and adverse clinical outcomes in PCI versus CABG at 5 years. CONCLUSIONS: Compliance with GDMT in contemporary clinical trials remains suboptimal and is significantly lower after CABG than after PCI, which may influence the comparison of clinical trial endpoints between those study groups.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pinho-Gomes AC, Azevedo L, Ahn JM, et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. J Am Coll Cardiol. 2018. PMID: 29420954. doi:10.1016/j.jacc.2017.11.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。